抗人IgA多克隆抗体ELISA法的建立和应用

用马抗人IgA抗体ELISA法,结合血清预处理,检测鼻咽癌(NPC)患者,其他肿瘤病人和正常人血清中的IgA/EA抗体结果表明,95.1％NPC病人阳性(抗体几何平均滴度为294.1),而健康对照组仅2.4～4.5％,ELISA与免疫酶染色(IE)法测得的血清抗体滴度之间有一定的相关性。但前者比后者测得的几何平均滴度(GMT)高9倍,本法敏感、特异、快速、简便,适用于现场大规模普查。     

血清中Epstein-Barr病毒膜抗原IgA抗体检测法的改进及应用

用萄葡球菌菌体A蛋白(SPA)预先处理被检血清,以去除抗体IgG部份的竞争性结合,提高了间接免疫荧光法检查鼻咽癌病人血清中EB病毒膜抗原IgA(IgA/MA)抗体的敏感性及特异性,检查48例鼻咽癌病人血清IgA/MA抗体,阳性率为100％,血清几何平均滴度为141;40例其它恶性肿瘤病人和46例正常人都检不出IgA/MA抗体,免疫荧光法测得IgA/MA抗体阴性的6例鼻咽癌病人血清,SPA吸收后呈阳性反应,此改进方法可用以追踪观察鼻咽癌病的病程及预后。     

用重组Epstein-Barr病毒早期蛋白P83为抗原检测鼻咽癌病人血清中IgA抗体

以重组EB病毒早期蛋白P83为抗原,用Western blot检测了135份鼻咽癌病人和100份正常人血清中IgA/P83抗体,阳性率分别为96％和0,以常规的间接免疫酶法检测这两种血清中IgA/EA抗体,阳性率分别为71％和0。IgA/P83抗体的几何平均滴度较IgA/EA高4倍以上。这表明,用Western blot查IgA/P83敏感、特异,可替代用间接免疫酶法查IgA/EA用于鼻咽癌的早期诊断。     

鼻咽癌患者血清中Epstein-Barr病毒早期抗原特异性抗体的IgA类抗独特型抗体的检测

用3.5％PEG(MW6000)预先处理被检血清以除掉免疫复合物及干扰抗原之后,用新建立的ELISA方法测定血清中Epstein-Barr病毒早期抗原特异性抗体的抗独特型(Anti-Id)抗体。67例鼻咽癌患者中,80％IgA类的Anti-Id抗体阳性(P/N值≥2.1),而56例正常人群除1例阳性外,其余均阴性。测定46例鼻咽癌患者血清EA/IgA滴度与Anti-Id的关系表明,Anti-Id抗体P/N值与IgA/EA滴度呈负相关(r=-0.6,P<0.001)。12例鼻咽癌病人血清中EA抗体的IgG类Anti-Id抗体则与正常人无显著差别。     

检查Epstein-Barr病毒IgA/EA抗体的ELISA法

建立了检查鼻咽癌病人血清中IgA/EA抗体的、改进的ELISA法,用巴豆油,正丁酸钠和阿糖胞苷激活并处理HRIK细胞株,使之表达EA抗原,提取抗原时加蛋白酶抑制剂,以增加产量和稳定性;用鼠抗人IgA单克隆抗体和兔抗鼠IgG抗血清的三层夹心法。提高了敏感性,使阳性检出率达到97％,而免疫酶法的阳性率仅60％,所用抗体工作浓度的几何平均稀释度为免疫酶法的8倍,两法抗体滴度的分布呈平行关系,本法适用于大规模现场普查和鼻咽癌的早期诊断,具有快速、特异和敏感等优点。     

用转染EB病毒基因片段的真核细胞检测鼻咽癌病人的抗EB病毒核抗原-1(EBNA-1)抗体

用转染EBV DNA Bam HI K片段后稳定表达EBNA-1的K_4细胞作为靶细胞,检测50份鼻咽癌病人和38份健康对照者血清中的IgG/EBNA-1抗体;阳性率分别为100％和92％。前者的平均几何滴度为89.4,后者为18.3,前者约为后者的5倍。同一批被检血清经SPA吸收去除IgG竞争性抑制后,鼻咽癌病人的IgA/EBNA-1抗体阳性率达78％(GMT 20.9),健康人的IgA/EBNA-1抗体阳性率仅5.3％,效价亦很低(GMT 5.2)。表明IgA/EBNA-1抗体对鼻咽癌是比较特异的,可考虑作为鼻咽癌血清学诊断的指标之一。     

应用基因重组Epstein-Barr病毒早期抗原P83蛋白检测鼻咽癌患者血清中的IgA/EA抗体

将pUCB质粒表达的P83蛋白应用于免疫印迹法(IB)和ELISA中,检测了85例鼻咽癌(NPC)患者和100例健康人血清,同时与免疫酶法(IE)作比较。结果表明,免疫印迹法对NPC患者血清阳性检出率为94％;ELISA法阳性检出率为88％;而IE法阳性率为64％。三种方法检测健康人血清出现低水平IgA/EA抗体的阳性率分别为4％、3％及2％。用IE法检测IgA/EA抗体为阴性的NPC患者血清,用IB法检测的阳性率达87％,ELISA法阳性检出率为77％。IB法与ELISA法之间具有较好的正相关(r=0.67,P<0.01)。     

EB病毒DNA聚合酶基因的表达与纯化及其在鼻咽癌病人诊断中的应用

以Epstein-Barr病毒(EBV)DNA聚合酶为抗原,建立了简便、快速、敏感和特异的鼻咽癌诊断方法.构建原核表达载体pRSET-DNA聚合酶及其亚克隆pRSET-A1和pRSET-A2,在BL21(DE3)中表达的产物,经Western-blot检测其抗原性并用于检测鼻咽癌(nasopharyngeal carcinoma,NPC)病人血清中的抗体.在NPC病人血清中存在抗EB病毒DNA聚合酶的IgG抗体,并证明DNA聚合酶的抗原性主要集中于后2/3片段(A2)上.Western-bolt检测A2/IgG抗体的敏感性和特异性分别为80%和100%.对46份NPC病人血清和46份非NPC头颈癌症病人血清,用ELISA检测A2/IgA,敏感度为89%,特异度为93%.初步建立了ELISA检测NPC病人血清中A2/IgG抗体的方法,获得较高的敏感性和特异性.     

捕捉法ELISA检测脊髓灰质炎IgA抗体方法的建立与应用

建立了一种检测脊髓灰质炎(简称脊灰)IgA抗体的捕捉法ELISA(Aac-ELISA)。方法敏感,快速,特异,用于检测144份脊灰可疑病人的血清,IgA抗体检出率为77.8％(112/144).而这些血清的IgM抗体检出率为65.2％(94/144)。如同时检测IgM和IgA抗体,则阳性率可达91.7％(132/144)。麻痹后1～3天内IgA的检出率为76.5％(13/17),4～7天内为95％(19/20)。最长检出IgA的一例可疑病人,其血清收集于病后第59天。本方法在一部分16天后可疑病人IgM阴性血清中查出IgA阳性,故可以作为查IgM抗体诊断方法的补充,尤其适用于诊断感染后未能及时收到血清标本,IgM已经转阴而IgA抗体仍为阳性的病人。     

用改进的测定Epstein-Barr病毒早期抗原IgA的方法为2054人检查鼻咽癌

应用测定Epstein-Barr病毒(EB病毒)IgA/EA抗体的改进方法(见病毒学报,2:372,1986).将待检血清用与抗人IgG血清或葡萄球菌菌体蛋白(SPA)吸附,除去了竞争性IgG类抗体,增加了血清中IgA抗体与抗原相结合的机率,从而提高了免疫酶法的敏感性和鼻咽癌的检出率。用此法我们检查了来本实验室检查EB病毒相关抗体的2045人,大部份是进行体格检查、无自觉症状的健康人,其查出IgA/EA抗体阳性者42人,进一步做病理检查证实27人患鼻咽癌,其中属临床Ⅰ期者10人,Ⅱ期10人,Ⅲ期6人,     

Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer

TheBamHI Z EBV replication activator (ZEBRA) protein is involved in the switch from latency to productive cycle of Epstein-Barr virus. A recombinant ZEBRA protein was synthesized and assessed in enzymelinked immunosorbent assay (ELISA) for serum IgG response in nasopharyngeal carcinoma (NPC) patients. In 100 NPC serum samples that were positive for IgA to the EBV viral capsid antigen (VCA), 75% had IgG anti-ZEBRA antibodies. In contrast, only 3/83 (3.6%) serum samples from healthy donors and 2/50 (4%) from other cancers were positive for IgG to ZEBRA. Interestingly, in a selected group of 100 NPC sera negative for IgA to VCA, 25% contained IgG anti-ZEBRA antibodies. This suggests that the ELISA for IgG anti-ZEBRA may also identify earlier cases of NPC not detected by the conventional immunofluorescence test for IgA to VCA.     

Changes in Epstein-Barr virus antibody titers associated with aging

Antibody titers to the Epstein-Barr virus (EBV), early antigen (EA) IgG, and virus capsid antigen (VCA) IgG and IgA, were measured in 44 geriatric subjects to determine if the depression in cellular immunity known to be associated with aging affects the expression of latent EBV. Similar assays were performed on plasma obtained from a young adult (medical student) population as a control group. We found that 89% of the geriatric samples were positive for EA IgG, and 83% of the plasma obtained from medical students were positive for EA IgG. One hundred percent of the geriatric subjects were positive for VCA IgG, and 87% of the medical students were positive for VCA IgG. Seven percent of the medical student blood samples were positive for VCA IgA; in contrast, 36% of the blood samples obtained from the geriatrics subjects were positive. Significant differences were also found in the geometric mean titers (GMT) of antibodies to EBV antigens; the GMT to EBV EA and VCA were significantly higher in the geriatric group. The data suggest that there may be some loss of control over latent EBV by the cellular immune response in geriatric individuals.     

应用蛋白印迹法检测鼻咽癌病人血清中抗Epstein—Barr病毒IgA/EA抗体

曾毅等建立了一系列检测EB病毒IgA/VCA和IgA/EA抗体的鼻咽癌早期诊断方法,取得了满意的结果。为了进一步提高对鼻咽癌诊断更为特异的IgA/EA抗体的检出率,我们建立了检测EB病毒IgA/EA抗体的蛋白印迹法。方法敏感特异,结果令人满意。 本法中所用的两个质粒系由本实验室与西德Pettenkofer研究所Wolf教授的实验室合作构建。pUCARG1140和pUC9MBcE3.2质粒均为表达质粒,前者携带着来源于EB病毒Bam     

鼻咽癌患者血清中抗Epstein-Barr病毒早期和晚期膜抗原抗体的检测

对Epstein-Barr(EB)病毒抗原的研究,发现有淋巴细胞确定的膜抗原(Lydma)、早期抗原(EA)、壳抗原(VCA)、核抗原(EBNA)、早期膜抗原(EMA)和晚期膜抗原(LMA)。除了Lydma抗原外,鼻咽癌患者对上述抗原均产生相应的IgG和IgA抗体。因而研究这些抗体,对阐明EB病毒与鼻咽癌的关系及鼻咽癌的早期诊断都十分有价值。